The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Company profile

RECURSION PHARMACEUTICALS, INC. insider acquisitions

Company CIK 0001601830 · Reported insider acquisitions and filing context.

Company filings at SEC ↗
RXRX · Nasdaq

These are company listings. A transaction is linked to a particular security only when the filing provides enough information.

Company activity summary

By transaction date, as of October 23, 2026.

7 days30 days90 daysOverlapping periods · securities and currencies kept separate
90-day company acquisitions grouped by security, category, original code, and currency.
Type / codeReported securityTransactionsKnown purchase valueMissing amounts
Stock awardCode AClass A Common StockNon-derivative · Currency not specified2Not applicable0
Exercise / conversionCode MClass A Common StockNon-derivative · Currency not specified1Not applicable0

Known purchase value sums available amounts for non-derivative purchases only. Missing amounts are excluded. “Currency not specified” does not establish that the amounts share a currency. These summaries use all matching loaded records, while the timeline below covers only the current page.

Transaction timeline

Who reported an acquisition, and when the transaction occurred.

Reported acquisitions by transaction dateEach row is a reporting owner. Select a marker to open its transaction details. Jointly reported transactions appear for each associated reporting owner, without dividing quantities or amounts.HERSHBERG ROBERTHERSHBERG ROBERTDar ZavainDar ZavainLi Dean YLi Dean YGibson ChristopherGibson ChristopherKhan NajatKhan NajatHERSHBERG ROBERT · October 6, 2026 · Exercise / conversion · Class A Common StockDar Zavain · October 1, 2026 · Stock award · Class A Common StockLi Dean Y · October 1, 2026 · Stock award · Class A Common StockGibson Christopher · December 19, 2025 · Conversion · Class A Common StockGibson Christopher · December 4, 2025 · Conversion · Class A Common StockGibson Christopher · November 19, 2025 · Conversion · Class A Common StockKhan Najat · November 5, 2025 · Stock award · Stock Option (Right to Buy)Khan Najat · November 5, 2025 · Stock award · Class A Common StockGibson Christopher · November 4, 2025 · Conversion · Class A Common StockGibson Christopher · October 23, 2025 · Conversion · Class A Common StockOct 23, 2025Oct 6, 2026
PurchaseStock awardGift receivedExercise / conversionConversionOther acquisition

10 dated transactions · 5 of 5 reporting owners shown. Select one owner to focus the chart.

View timeline as a table
Transaction dateCompany / securityReporting ownersAcquisition type
Oct 6, 2026RECURSION PHARMACEUTICALS, INC.Class A Common StockHERSHBERG ROBERTExercise / conversion
Oct 1, 2026RECURSION PHARMACEUTICALS, INC.Class A Common StockDar ZavainStock award
Oct 1, 2026RECURSION PHARMACEUTICALS, INC.Class A Common StockLi Dean YStock award
Dec 19, 2025RECURSION PHARMACEUTICALS, INC.Class A Common StockGibson ChristopherConversion
Dec 4, 2025RECURSION PHARMACEUTICALS, INC.Class A Common StockGibson ChristopherConversion
Nov 19, 2025RECURSION PHARMACEUTICALS, INC.Class A Common StockGibson ChristopherConversion
Nov 5, 2025RECURSION PHARMACEUTICALS, INC.Stock Option (Right to Buy)Khan NajatStock award
Nov 5, 2025RECURSION PHARMACEUTICALS, INC.Class A Common StockKhan NajatStock award
Nov 4, 2025RECURSION PHARMACEUTICALS, INC.Class A Common StockGibson ChristopherConversion
Oct 23, 2025RECURSION PHARMACEUTICALS, INC.Class A Common StockGibson ChristopherConversion

Only transactions on this page are shown. Date windows end on the latest transaction date in this sample. Joint filings may appear on more than one row. Sales are not included. Share-price charts use a separate data source.

Share price & reported acquisitions

Daily closing prices from a separate source. The date window above also filters prices; reporting-owner and transaction-type selections filter the markers.

Price history is not available

Market-price history is not connected yet.

RXRX · Currency not specified. A marker uses that day's closing price, not the reported transaction price. No price is substituted for a missing trading day.

Reported acquisitions

Filing-date filters apply to the list and timeline. The summary above uses transaction dates.

Reset
Reported insider acquisitions, ordered by filing date, newest first. Currency is shown only when reported.
Filed / transactedReporting ownersType / securityQuantityPrice / reference valueDetails
Trade: Exercise / conversionClass A Common StockNon-derivative security · Code M25,0002.22Value: 55,500Currency not specifiedView ↗
Trade:
Dar ZavainDirector
Stock awardClass A Common StockNon-derivative security · Code A4,6070Value: 0Currency not specifiedView ↗
Trade:
Li Dean YDirector
Stock awardClass A Common StockNon-derivative security · Code A3,3780Value: 0Currency not specifiedView ↗
Trade:
Gibson ChristopherChief Executive Officer · Director
ConversionClass A Common StockNon-derivative security · Code C40,0000Value: 0Currency not specifiedView ↗
Trade:
Gibson ChristopherChief Executive Officer · Director
ConversionClass A Common StockNon-derivative security · Code C60,0000Value: 0Currency not specifiedView ↗
Trade:
Gibson ChristopherChief Executive Officer · Director
ConversionClass A Common StockNon-derivative security · Code C40,0000Value: 0Currency not specifiedView ↗
Trade:
Khan NajatChief R&D Commercial Officer · Director
Stock awardStock Option (Right to Buy)Derivative security · Code A169,8510Value: 0Currency not specifiedView ↗
Trade:
Khan NajatChief R&D Commercial Officer · Director
Stock awardClass A Common StockNon-derivative security · Code A84,9250Value: 0Currency not specifiedView ↗
Trade:
Gibson ChristopherChief Executive Officer · Director
ConversionClass A Common StockNon-derivative security · Code C60,0000Value: 0Currency not specifiedView ↗
Trade:
Gibson ChristopherChief Executive Officer · Director
ConversionClass A Common StockNon-derivative security · Code C100,0000Value: 0Currency not specifiedView ↗

Reporting owners are associated with a filing. Jointly reported amounts are not allocated to individual owners. Historical coverage is still being built. Read the methodology →